Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026
Company Drug

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

Fineline Cube Apr 21, 2026
Company Drug

Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers

Fineline Cube Apr 21, 2026
Company Drug

Mabwell Bioscience Receives NMPA Approval for Phase II TNBC Clinical Trial of 9MW2821

Fineline Cube Jul 16, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that China’s National Medical Products Administration...

Company Deals

Lionco Pharmaceutical Partners with Laboratoire Bailly-Creat to Expand Overseas

Fineline Cube Jul 16, 2024

Shanghai-based Lionco Pharmaceutical Group (SHA: 603669) has entered into a strategic partnership framework agreement with...

Company Policy / Regulatory

Novo Nordisk Faces US Senators’ Scrutiny Over Levemir Withdrawal

Fineline Cube Jul 16, 2024

US senators, including Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren, have voiced concerns over Novo...

Company

Johnson & Johnson Appoints Edward Zhou as Medtech China President

Fineline Cube Jul 16, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a global healthcare giant, has announced the appointment of...

Company Drug

Ipsen S.A. Receives NMPA Green Light for Six-Month Diphereline Dosage in Central Precocious Puberty

Fineline Cube Jul 16, 2024

Ipsen S.A. (EPA: IPN; OTCMKTS: IPSEY) has announced that it has received marketing approval from...

Company Drug

Shanghai HeartCare Medical Secures Taiwan Approval for Homegrown Femoral Artery Occluder

Fineline Cube Jul 16, 2024

Shanghai HeartCare Medical Technology Co., Ltd (HKG: 6609), a leading player in the Chinese medical...

Drug Legal / IP Policy / Regulatory

U.S. Senate Passes Affordable Prescriptions for Patients Act to Limit Patent Thicketing

Fineline Cube Jul 15, 2024

In a significant move to curb drug prices, the U.S. Senate unanimously passed the Affordable...

Company Deals

Nona Biosciences Partners with Alaya.bio to Revolutionize CAR-T Therapy Development

Fineline Cube Jul 15, 2024

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...

Company Drug

Eisai’s Next-Gen SERD, Orserdu, Begins Real-World Study in Shanghai Ruijin Hospital’s Hainan Subsidiary

Fineline Cube Jul 15, 2024

Shanghai Ruijin Hospital’s Hainan subsidiary has initiated a real-world study for Orserdu (elacestrant), a next-generation...

Company Drug

Everest Medicines’ Velsipity Shows Positive Results in Largest Asian Phase III UC Trial

Fineline Cube Jul 15, 2024

Everest Medicines (HKG: 1952), a leading biopharmaceutical company based in China, has announced positive top-line...

Company Drug

Huadong Medicine’s Partner Arcutis Gets FDA Nod for Roflumilast Cream

Fineline Cube Jul 15, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, announced that its co-development partner...

Company Deals Medical Device

Mindray Bio-Medical Partners with Nanjing Municipal Government to Boost Healthcare Innovation

Fineline Cube Jul 15, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a leading player in the global medical...

Company Deals

Shenzhen-Based National Biological Manufacturing Innovation Center Breaks Ground

Fineline Cube Jul 15, 2024

Construction has commenced on a pioneering national biological manufacturing industry innovation center in Shenzhen, marking...

Company Deals Digital

E-Health Now Secures USD 13.8 Million in Series C Financing to Expand AI Medical Services

Fineline Cube Jul 15, 2024

E-Health Now, a China-based one-stop artificial intelligence (AI)-powered medical health service platform, has reportedly secured...

Company

Merck KGaA Launches First GMP Cell Culture Medium Production Line in China

Fineline Cube Jul 15, 2024

German pharmaceutical giant Merck KGaA (ETR: MRK) has announced the commencement of commercial manufacturing of...

Company Deals

AusperBio Secures $37 Million in Series A Funding to Advance Hepatitis B Therapy AHB-137

Fineline Cube Jul 15, 2024

AusperBio, a sino-American biotechnology company specializing in liver therapy development, has reportedly secured USD 37...

Company Drug

Mabwell Bioscience’s 9MW2821 Earns FDA Fast Track Designation for Triple Negative Breast Cancer

Fineline Cube Jul 15, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Deals

Shanghai Duoning Biotechnology Partners with BASF SE to Commercialize Medical Materials in China

Fineline Cube Jul 15, 2024

Shanghai Duoning Biotechnology Co., Ltd, a prominent player in China’s biopharmaceutical industry, has entered into...

Company Drug

NMPA Accepts 3SBio’s Filing for Anemia Treatment SSS06, Potential Game Changer for Dialysis Patients

Fineline Cube Jul 15, 2024

3SBio Inc. (HKG: 1530), a leading biopharmaceutical company based in China, has announced that the...

Company Deals

Baheal Pharmaceutical Group to Launch Industry Fund Focused on Life Sciences

Fineline Cube Jul 15, 2024

China’s leading health services and distribution conglomerate, Baheal Pharmaceutical Group, is venturing into the investment...

Posts pagination

1 … 318 319 320 … 654

Recent updates

  • Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026
  • Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers
  • LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment
  • Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication
  • UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

Company Drug

Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers

Company Drug

LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment

Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.